Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

| More on:
A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares are still up significantly over the past five years, despite a recent slump
  • This ASX cannabis share has some exciting cannabis and psilocybin drugs in its pipeline
  • However, Incannex is still burning money and is receiving nothing in terms of revenue

It was only last month that we were discussing Incannex Healthcare Ltd (ASX: IHL) shares and the epic run they had been on over the previous five years.

Yes, back in May, investors who had held onto Incannex shares were up a lucrative 425% from May 2018. Today, the same gains hold, with the Incannex share price notching a five-year gain of 435% on current pricing.

However, the fact remains that Incannex shares, while still a great long-term performer, are also down significantly from their recent highs. In fact, this ASX cannabis share is currently trading at a multi-year low.

At present, the Incannex share price is going for 10.7 cents a share, up 1.9% for the day so far. At this level, the company has lost more than 40% from the 19 cents per share levels we saw back in January. Investors are also down a nasty 82% or so from the high we saw back in March 2022, when Incannex touched the 60-cent mark, as you can see below:


So this rather volatile journey might posit the question today: are Incannex shares still worth buying at these multi-year lows?

Are Incannex shares a buy today?

Incannex is certainly doing some exciting work. This ASX cannabis share specialises in finding cannabis-based medical solutions. Back in March, the company announced it would be developing a psilocybin-based drug to help combat anxiety disorders for clinical trials.

Last month, it also announced the appointment of Dr John Hudson and Dr Russell Rosenberg to lead its phase two and three clinical trials for a cannabis-based drug for the treatment of sleep apnoea.

However, hope and dreams are not enough to warrant an investment in my view. At its core, Incannex is still a loss-making company. Its quarterly cash flow statement from April revealed that Incannex has received exactly $0 in revenues while burning through $4.29 million in cash.

As of the report, the company has just over $37 million in cash left over. Its activities are currently being funded through capital raisings and issuances of new shares. In other words, shareholders.

Now if Incannex can pull off the creation of a new cannabis- or psilocybin-based wonder drug, then this might all be worth it and the shares could look cheap in hindsight.

But to me, this looks like a lottery-ticket investment (win big or lose it all). And I don't do lottery ticket investments. So I'll be avoiding Incannex shares for now, although the company has my sincerest best wishes for the future.


Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »

little green pharma share price represented by cannabis leaf character jumping cheerfully
Cannabis Shares

Little Green Pharma share price shoots 13% higher after capital raise

There's considerable excitement in the medicinal cannabis space as Australia becomes the world's first market to recognise psychedelics as medicines.

Read more »